223 related articles for article (PubMed ID: 23287700)
21. Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.
Stewart JL; McMahon LR
J Pharmacol Exp Ther; 2010 Jul; 334(1):347-56. PubMed ID: 20375197
[TBL] [Abstract][Full Text] [Related]
22. Cannabinoid CB
He XH; Jordan CJ; Vemuri K; Bi GH; Zhan J; Gardner EL; Makriyannis A; Wang YL; Xi ZX
Acta Pharmacol Sin; 2019 Mar; 40(3):365-373. PubMed ID: 29967454
[TBL] [Abstract][Full Text] [Related]
23. Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties.
Bergman J; Delatte MS; Paronis CA; Vemuri K; Thakur GA; Makriyannis A
Physiol Behav; 2008 Mar; 93(4-5):666-70. PubMed ID: 18076956
[TBL] [Abstract][Full Text] [Related]
24. Apparent Affinity Estimates and Reversal of the Effects of Synthetic Cannabinoids AM-2201, CP-47,497, JWH-122, and JWH-250 by Rimonabant in Rhesus Monkeys.
Hruba L; McMahon LR
J Pharmacol Exp Ther; 2017 Aug; 362(2):278-286. PubMed ID: 28533288
[TBL] [Abstract][Full Text] [Related]
25. The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability.
Gueye AB; Pryslawsky Y; Trigo JM; Poulia N; Delis F; Antoniou K; Loureiro M; Laviolette SR; Vemuri K; Makriyannis A; Le Foll B
Int J Neuropsychopharmacol; 2016 Dec; 19(12):. PubMed ID: 27493155
[TBL] [Abstract][Full Text] [Related]
26. Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT
McLaughlin PJ; Jagielo-Miller JE; Plyler ES; Schutte KK; Vemuri VK; Makriyannis A
Psychopharmacology (Berl); 2017 Mar; 234(6):1029-1043. PubMed ID: 28144708
[TBL] [Abstract][Full Text] [Related]
27. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
Darmani NA
Neuropsychopharmacology; 2001 Feb; 24(2):198-203. PubMed ID: 11120402
[TBL] [Abstract][Full Text] [Related]
28. JWH-018 and JWH-073: Δ⁹-tetrahydrocannabinol-like discriminative stimulus effects in monkeys.
Ginsburg BC; Schulze DR; Hruba L; McMahon LR
J Pharmacol Exp Ther; 2012 Jan; 340(1):37-45. PubMed ID: 21965552
[TBL] [Abstract][Full Text] [Related]
29. Sex differences in cannabinoid 1 vs. cannabinoid 2 receptor-selective antagonism of antinociception produced by delta9-tetrahydrocannabinol and CP55,940 in the rat.
Craft RM; Wakley AA; Tsutsui KT; Laggart JD
J Pharmacol Exp Ther; 2012 Mar; 340(3):787-800. PubMed ID: 22182934
[TBL] [Abstract][Full Text] [Related]
30. Evidence for both inverse agonism at the cannabinoid CB1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation.
Makwana R; Molleman A; Parsons ME
Br J Pharmacol; 2010 Jun; 160(3):615-26. PubMed ID: 20590566
[TBL] [Abstract][Full Text] [Related]
31. Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats.
Pavón FJ; Serrano A; Pérez-Valero V; Jagerovic N; Hernández-Folgado L; Bermúdez-Silva FJ; Macías M; Goya P; de Fonseca FR
J Neuroendocrinol; 2008 May; 20 Suppl 1():116-23. PubMed ID: 18426510
[TBL] [Abstract][Full Text] [Related]
32. Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats.
Calik MW; Carley DW
Sleep; 2017 Sep; 40(9):. PubMed ID: 28934522
[TBL] [Abstract][Full Text] [Related]
33. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.
Klumpers LE; Fridberg M; de Kam ML; Little PB; Jensen NO; Kleinloog HD; Elling CE; van Gerven JM
Br J Clin Pharmacol; 2013 Dec; 76(6):846-57. PubMed ID: 23601084
[TBL] [Abstract][Full Text] [Related]
34. In-vivo pharmacological evaluation of the CB1-receptor allosteric modulator Org-27569.
Gamage TF; Ignatowska-Jankowska BM; Wiley JL; Abdelrahman M; Trembleau L; Greig IR; Thakur GA; Tichkule R; Poklis J; Ross RA; Pertwee RG; Lichtman AH
Behav Pharmacol; 2014 Apr; 25(2):182-5. PubMed ID: 24603340
[TBL] [Abstract][Full Text] [Related]
35. Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice.
McMahon LR; Koek W
Eur J Pharmacol; 2007 Aug; 569(1-2):70-6. PubMed ID: 17553486
[TBL] [Abstract][Full Text] [Related]
36. Partial agonist-like profile of the cannabinoid receptor antagonist SR141716A in a food-reinforced operant paradigm.
De Vry J; Jentzsch KR
Behav Pharmacol; 2004 Feb; 15(1):13-20. PubMed ID: 15075622
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.
Rock EM; Sticht MA; Duncan M; Stott C; Parker LA
Br J Pharmacol; 2013 Oct; 170(3):671-8. PubMed ID: 23902479
[TBL] [Abstract][Full Text] [Related]
38. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.
Seely KA; Brents LK; Franks LN; Rajasekaran M; Zimmerman SM; Fantegrossi WE; Prather PL
Neuropharmacology; 2012 Oct; 63(5):905-15. PubMed ID: 22771770
[TBL] [Abstract][Full Text] [Related]
39. Δ
Gatch MB; Forster MJ
Psychopharmacology (Berl); 2018 Mar; 235(3):673-680. PubMed ID: 29138877
[TBL] [Abstract][Full Text] [Related]
40. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
